JFL Life Sciences Ltd
Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations[1]
- Market Cap ₹ 66.0 Cr.
- Current Price ₹ 10.0
- High / Low ₹ 18.8 / 8.55
- Stock P/E 10.3
- Book Value ₹ 6.95
- Dividend Yield 0.00 %
- ROCE 18.2 %
- ROE 15.0 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 64.0% CAGR over last 5 years
- Company's working capital requirements have reduced from 134 days to 103 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.2% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 32 | 30 | 33 | 34 | 43 | 47 | 82 | 131 | |
| 30 | 28 | 31 | 28 | 39 | 42 | 74 | 120 | |
| Operating Profit | 1 | 2 | 2 | 5 | 4 | 5 | 8 | 12 |
| OPM % | 4% | 6% | 7% | 16% | 9% | 10% | 10% | 9% |
| 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Profit before tax | 0 | 0 | 1 | 4 | 4 | 4 | 6 | 9 |
| Tax % | 28% | 29% | 27% | 26% | 25% | 13% | 32% | 26% |
| 0 | 0 | 1 | 3 | 3 | 3 | 4 | 6 | |
| EPS in Rs | 1.25 | 1.50 | 1.50 | 0.59 | 0.43 | 0.50 | 0.63 | 0.97 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 8% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 45% |
| TTM: | 60% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 64% |
| 3 Years: | 32% |
| TTM: | 54% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -10% |
| 1 Year: | -47% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 12% |
| Last Year: | 15% |
Balance Sheet
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.50 | 8 | 11 | 11 | 33 | 33 |
| Reserves | 5 | 5 | 6 | 3 | 21 | 25 | 6 | 13 |
| 8 | 9 | 17 | 16 | 7 | 6 | 11 | 22 | |
| 3 | 10 | 5 | 21 | 10 | 15 | 22 | 39 | |
| Total Liabilities | 16 | 24 | 29 | 48 | 49 | 57 | 72 | 106 |
| 2 | 5 | 6 | 7 | 7 | 12 | 12 | 15 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 14 | 19 | 23 | 41 | 42 | 44 | 60 | 92 | |
| Total Assets | 16 | 24 | 29 | 48 | 49 | 57 | 72 | 106 |
Cash Flows
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| -3 | 3 | -6 | 2 | -9 | 8 | -4 | -4 | |
| -1 | -3 | -2 | -1 | 1 | -6 | -0 | -4 | |
| 4 | -0 | 7 | -1 | 8 | -2 | 4 | 9 | |
| Net Cash Flow | 0 | 0 | -0 | 0 | -0 | -0 | 0 | 1 |
| Free Cash Flow | -4 | 0 | -8 | 1 | -9 | 2 | -4 | -8 |
| CFO/OP | -225% | 177% | -268% | 41% | -206% | 185% | -31% | -37% |
Ratios
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 111 | 153 | 132 | 215 | 192 | 203 | 155 | 148 |
| Inventory Days | 21 | 52 | 72 | 212 | 130 | 145 | 128 | 110 |
| Days Payable | 18 | 122 | 58 | 218 | 76 | 114 | 98 | 93 |
| Cash Conversion Cycle | 115 | 83 | 146 | 208 | 246 | 233 | 186 | 165 |
| Working Capital Days | 62 | 7 | 74 | 117 | 221 | 177 | 124 | 103 |
| ROCE % | 12% | 10% | 23% | 15% | 12% | 16% | 18% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Revenue from Operations Growth percentage |
|
|||
| Trade Receivable Turnover Ratio ratio |
||||
| Number of New Pharma Products Launched (Domestic) number |
||||
| Specific Order: J D Healthcare (Pharma Supply) INR Crores |
||||
| Specific Order: Phil Capital Trading Solutions Inc (International Capsule Manufacturing) USD Millions |
||||
| Total Permanent Employees number |
||||
Extracted by Screener AI
Documents
Announcements
-
Disclosure under SEBI Takeover Regulations
5 June 2026 - SMIRAL ASHWINKUMAR PATEL has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, …
-
Disclosure under SEBI Takeover Regulations
5 June 2026 - Jfl Life Sciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) …
-
Copy of Newspaper Publication
30 May 2026 - Published audited financial results for quarter and year ended 31 March 2026 on 30 May 2026.
-
Appointment
29 May 2026 - JFL Life Sciences appoints Mr. Jignesh Sharma as internal auditor for FY2026-27 on May 29, 2026.
-
Updates
29 May 2026 - Board approved audited FY26 results, unmodified audit opinion, appointed internal auditor, and filed related party transactions.
Business Overview:[1]
JFLLSL is a WHO-GMP Certified pharmaceutical company that manufactures and sells products across multiple markets. It specializes in Dry Powder Injectable Solid Oral Dosage Forms (Beta-Lactam & General)